CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Omega Therapeutics, a genomic medicines company, today announced that it will deliver a corporate presentation at BIO Digital, the virtual format of the BIO International Convention, to be held June 8-12, 2020. Omega’s transformative development platform focuses on enabling the future of disease management and prevention by selectively directing and tuning genomic activity to treat and cure diseases across multiple therapeutic areas.

Mahesh Karande, the Company’s President and Chief Executive Officer, will give a corporate overview via webcast, made available June 8, 2020 at 12:00pm ET. The presentation will also be recorded and made available on demand for 30 days beginning June 8, 2020.

In addition, members of the Omega Therapeutics management team will be available for virtual meetings throughout BIO Digital. To arrange a meeting with management, please contact Chinmaya Rath at crath@omegatherapeutics.com or visit the BIO One-on-One Partnering Portal to schedule a meeting.

About Omega Therapeutics

Omega Therapeutics is a platform company advancing novel engineered therapeutics called Omega Controllers™ into clinical development for a broad range of indications. These therapeutics control Insulated Genomic Domains (IGDs), the fundamental structural and functional units of genomic regulation, through epigenetic modulation to deliver Precision Genomic Control™. IGDs encompass single or multiple genes and their associated regulatory elements, and are correlated with diverse diseases, including cancer, autoimmune, inflammatory, regenerative, metabolic, neurological conditions and rare diseases. Omega Controllers™ deliver the required potent and durable therapeutic effect by precisely tuning single and/or multiple genes with high specificity to unleash the human genome’s native capacity to cure disease without altering nucleic acid sequences.

Founded by Flagship Pioneering in 2017, Omega’s platform and knowledge base identify and map IGDs and their structure and function in both healthy and diseased states across cell types. This scientific insight drives the discovery and development of novel Omega Controllers™, intended for clinical development across a range of therapeutic indications. To learn more please visit www.omegatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005189/en/